Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

554
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
554

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Type I interferon-activated NK cells control polycythemia vera in vivo.

Blood·2026
Same author

Noninvasive in vivo imaging of NF-κB activation predicts immunotherapy response in solid tumors.

Npj imaging·2026
Same author

Dual inhibition of PP2A and WEE1 induces apoptosis and mitotic catastrophe in cancer cells.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Inhibition of p300/CREBBP catalytic activity drives context-dependent transcriptional activation in AML.

Blood·2026
Same author

Characterization of the TREM-1 signaling landscape in human neutrophils.

PloS one·2026
Same author

B cells maintain the homeostasis of splenic marginal zone antigen-presenting cells to promote the antiviral CD8<sup>+</sup> T-cell response.

Cellular & molecular immunology·2026

Related Experiment Video

Updated: Jul 16, 2025

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.3K

Optimized dithranol-imiquimod-based transcutaneous immunization enables tumor rejection.

Ann-Kathrin Hartmann1, Joschka Bartneck1, Jonas Pielenhofer2

  • 1IIIrd Department of Medicine - Hematology and Oncology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.

Frontiers in Immunology
|September 20, 2023
PubMed
Summary

Optimized transcutaneous immunization (TCI) using the DIVA platform with dithranol and imiquimod (IMQ) enhances T cell responses. This non-invasive method effectively controls tumor growth, showing promise for cancer vaccines.

Keywords:
cytotoxic T lymphocytes (CTL)dithranol (anthralin)imiquimod (IMQ)trancutaneous immunizationtumor rejection

More Related Videos

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.6K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K

Related Experiment Videos

Last Updated: Jul 16, 2025

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.3K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.6K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K

Area of Science:

  • Immunology
  • Vaccinology
  • Dermatology

Background:

  • Transcutaneous immunization (TCI) is a non-invasive vaccination strategy that elicits robust cellular immunity, vital for cancer rejection.
  • The DIVA (dithranol/IMQ based vaccination) platform combines imiquimod (IMQ) and dithranol for TCI, previously showing promise.
  • Further optimization of the DIVA platform focused on drug dosage, application methods, and a new IMQ formulation.

Purpose of the Study:

  • To optimize the DIVA transcutaneous immunization platform for enhanced T cell responses and cancer immunotherapy.
  • To investigate the impact of adjuvant dose, application site, and order on immune responses and inflammation.
  • To evaluate a new nanocrystalline imiquimod formulation (IMI-Sol+) for improved storage and application.

Main Methods:

  • C57BL/6 mice were immunized with ovalbumin-derived peptides using dithranol and IMQ ointments applied to ear skin.
  • T cell responses were quantified using flow cytometry and IFN-γ ELISpot assays.
  • Local skin inflammation was assessed by measuring ear swelling.

Main Results:

  • Optimal T cell priming required co-localization of adjuvants and peptide antigens on the skin.
  • Dithranol's application order was critical for superior T cell responses, while IMQ formulation (IMI-Sol+) improved handling without compromising efficacy.
  • DIVA boosted antigen-specific T cells and memory responses significantly, with double treatment providing complete tumor protection in a prophylactic model.

Conclusions:

  • Optimized DIVA transcutaneous immunization generates potent cellular immune responses crucial for effective tumor growth control.
  • This enhanced TCI method demonstrates significant potential for clinical development as a non-invasive cancer vaccine strategy.